Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Performance Evaluation of the C2i-Test for Detecting Molecular Residual Disease (MRD) in Bladder Cancer Patients.

NCT05221827 is registered in ClinicalTrials.gov with C2i Genomics as lead sponsor.

NCT NCT05221827
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05221827 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Performance Evaluation of the C2i-Test for Detecting Molecular Residual Disease (MRD) in Bladder Cancer Patients.
Lead sponsor
C2i Genomics
Phase
Observational
Overall status
Terminated
Start date
February 24, 2022
Completion date
July 27, 2022
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

muscle-invasive bladder carcinoma